1. HBW Insight
  2. >>Ingredients & Safety

CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request

 
• By Lauren Nardella

Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.

Conceptual image of CBD legalization and use.

Cosmetic Ingredient Review’s Expert Panel For Cosmetic Ingredient Safety will prioritize cannabidiol for review in 2024 at the US Food and Drug Administration’s request.

The agency initially asked the panel to add CBD to its list of 2020 priorities, but CBD had no reported...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

EFSA: ‘A Dose Of Estragole Without A Harmful Effect Cannot Be Established’

 
• By David Ridley

Dietary supplements containing estragole may have to be removed from the European Union market due to carcinogenic risk, according to a draft scientific opinion from EFSA that is currently out for consultation.

Urban Wastewater Directive: AESGP Requests Intervention In EFPIA’s Legal Action

 
• By David Ridley

AESGP has formally submitted a request to the General Court of the European Union to intervene in the European Federation of Pharmaceutical Industries and Association’s legal action against the revised EU Urban Wastewater Directive.

Gardenia Blue, OrangeOvation, StellarYellow Latest Natural Pivots In US Food Color Market

 
• By Malcolm Spicer

FDA’s fourth approval in past two months for color derived from natural sources to use in foods is Gardenia Blue Interest Group’s color additive petition for gardenia blue. Lycored launches StellarYellow and C Clear as alternatives for synthetic dyes yellow Nos. 5 and 6 and OrangeOvation C Clear for

House OMUFA Reauthorization Bill Takes On Clarifying Standards For Tests To Meet GRASE

 
• By Malcolm Spicer

Health Subcommittee will discuss reauthorizing OMUFA during a hearing on how to “maintain and improve” the public health workforce and rural health as well as access to OTC medicines.

More from HBW Insight

PCPC: US Sunscreen Regs, State Recycling Laws A Burden For Trade

 
• By Lauren Nardella

The Personal Care Products Council identifies sunscreen regulations among federal laws that place US industry at a competitive disadvantage, in comments to the Federal Trade Commission and the US Department of Justice Antitrust Division.

Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’

 
• By Malcolm Spicer

PCH lowers full-year guidance even after reaching $100m deal to acquire Canadian sterile ophthalmic manufacturer for its Clears Eyes line troubled by supply slumps for several years. Its $47.5m reported net sales for April-June period were down 6% from a year ago.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 
• By Derrick Gingery

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?